Prakiraan pendapatan perusahaan: fsdpharma.com (HUGE)

On GURU.Markets, the product sales volume forecast demonstrates a trend where the value of 0.00 aligns with the current metric. Risks for FSD Pharma Inc. (HUGE) are increasing due to a capital shortage and a lack of approved drugs. Unstable leadership strategies and share dilution are eroding confidence in management. However, patents for synthetic cannabinoids create venture potential that requires long-term R&D funding.

Volume dodolan sing dikarepake perusahaan: FSD Pharma, Inc. (HUGE) kanggo 04.07.2022 - 15.08.2024

Ringkesan rincian data analitis FSD Pharma Inc. (HUGE)

- nilai saham lan prakiraan konsensus rega:

Bagan rega FSD Pharma, Inc.|HUGE - Rata-rata rega prakiraan

- indikator kapitalisasi bursa perusahaan:

Nilai pasar FSD Pharma Inc.|HUGE - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Aset Bersih saben Siji Saham FSD Pharma|HUGE - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku fsdpharma.com|HUGE - Aset Neraca Perusahaan

- statistik kawajiban utang lan likuiditas:

Rasio Total Utang marang Ekuitas FSD Pharma Inc.|HUGE - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal FSD Pharma|HUGE - Gunggung tanggungan utang perusahaan|Rasio utang marang kapitalisasi buku FSD Pharma Inc.|HUGE - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan FSD Pharma|Indikator likuiditas cepet fsdpharma.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

HUGE - Bathi pungkasan|Bathi sing dikarepake FSD Pharma Inc.|HUGE - Kapitalisasi marang bathi resik|Pangali Forward P/E FSD Pharma|HUGE - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA FSD Pharma|HUGE - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan FSD Pharma|HUGE - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan fsdpharma.com|HUGE - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep FSD Pharma Inc.

- data dodolan lan asil:

HUGE - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan FSD Pharma Inc.|HUGE - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S FSD Pharma Inc.

Pambiji fundamental perusahaan:HUGE FSD Pharma, Inc.

The specifics of the sovereign cycle of FSD Pharma Inc. (HUGE) make this indicator a key filter for assessing revenue stability. This metric eliminates market noise and price anomalies, revealing the true fundamental potential of product realization. By analyzing the company's target sales dynamics, an investor sees forecasts stripped of emotional volatility. Peaks signal overvaluation, while dips indicate the asset is undervalued. Stable demand for innovation confirms the issuer's defensive profile.

Pesaing utama

Prakiraan pendapatan perusahaan Jazz Pharmaceuticals Corp (JAZZ)|CYTK - Volume dodolan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan PTC Therapeutics Corp PTCT|Scholar Rock Inc. - Prakiraan pendapatan perusahaan|CNTA - Prakiraan pendapatan perusahaan|Prakiraan dodolan perusahaan Dyne Therapeutics (DYN)|EWTX: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Rapport Pharma RAPP|Volume dodolan mangsa ngarep perusahaan ALMS|Volume dodolan sing dikarepake perusahaan Zevra Therapeutics ZVRA|Prakiraan volume dodolan CTNM|Prakiraan pendapatan perusahaan LRMR (Larimar Therapeutics)|Prakiraan volume dodolan CAPR (Capricor Therapeutics Inc.)|TRDA: Prakiraan pendapatan perusahaan|Channel Therapeutics Inc. - Prakiraan volume dodolan|MNOV (medicinova.com) - Prakiraan pendapatan perusahaan|Serina Therapeutics (SER) - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan BTAI|Prakiraan pendapatan perusahaan ProMIS Neurosciences, Inc.|Volume dodolan sing dikarepake perusahaan Apimeds Pharmaceuticals APUS|Prakiraan volume dodolan AEON|NLSP (NLS Pharmaceutics) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan BNOX (bionomics.com.au)|RETA (Reata Pharmaceuticals) - Pendapatan sing dikarepake perusahaan